JLB & Associates Inc. Lowers Holdings in Henry Schein, Inc. $HSIC

JLB & Associates Inc. trimmed its position in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 11.1% during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 67,438 shares of the company’s stock after selling 8,458 shares during the quarter. JLB & Associates Inc.’s holdings in Henry Schein were worth $4,476,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of HSIC. AQR Capital Management LLC grew its holdings in shares of Henry Schein by 47.3% during the first quarter. AQR Capital Management LLC now owns 30,402 shares of the company’s stock valued at $2,071,000 after buying an additional 9,756 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Henry Schein by 1.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 16,859 shares of the company’s stock valued at $1,155,000 after acquiring an additional 229 shares in the last quarter. Acadian Asset Management LLC purchased a new stake in Henry Schein during the 1st quarter valued at $676,000. Wealth Enhancement Advisory Services LLC boosted its stake in Henry Schein by 5.9% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 56,277 shares of the company’s stock valued at $4,202,000 after purchasing an additional 3,143 shares during the last quarter. Finally, Assenagon Asset Management S.A. increased its holdings in shares of Henry Schein by 165.5% in the 2nd quarter. Assenagon Asset Management S.A. now owns 45,066 shares of the company’s stock worth $3,292,000 after purchasing an additional 28,089 shares in the last quarter. 96.62% of the stock is currently owned by institutional investors.

Henry Schein Price Performance

NASDAQ HSIC opened at $78.47 on Friday. Henry Schein, Inc. has a 52 week low of $60.56 and a 52 week high of $82.49. The firm has a market capitalization of $9.24 billion, a P/E ratio of 24.83, a PEG ratio of 2.35 and a beta of 0.88. The company has a quick ratio of 0.79, a current ratio of 1.40 and a debt-to-equity ratio of 0.54. The company has a 50-day moving average price of $75.74 and a 200-day moving average price of $70.67.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings data on Tuesday, November 4th. The company reported $1.38 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.27 by $0.11. Henry Schein had a net margin of 3.02% and a return on equity of 14.76%. The company had revenue of $3.34 billion for the quarter, compared to the consensus estimate of $3.28 billion. Henry Schein has set its FY 2025 guidance at 4.880-4.960 EPS. Equities research analysts anticipate that Henry Schein, Inc. will post 4.74 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the company. Evercore ISI upped their price target on Henry Schein from $83.00 to $90.00 and gave the company an “outperform” rating in a report on Wednesday, November 5th. Weiss Ratings restated a “hold (c)” rating on shares of Henry Schein in a research note on Monday, December 29th. Wall Street Zen upgraded shares of Henry Schein from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. JPMorgan Chase & Co. boosted their price objective on shares of Henry Schein from $76.00 to $78.00 and gave the company an “overweight” rating in a report on Wednesday, November 5th. Finally, Morgan Stanley increased their price objective on shares of Henry Schein from $55.00 to $58.00 and gave the company an “underweight” rating in a research report on Wednesday, November 5th. Five research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $76.42.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.